{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:39:34Z","timestamp":1789587574725,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T00:00:00Z","timestamp":1348531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1472-6750-12-68","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T02:15:02Z","timestamp":1348539302000},"source":"Crossref","is-referenced-by-count":34,"title":["Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion"],"prefix":"10.1186","volume":"12","author":[{"given":"Mengyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"issue":"6937","key":"753_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423 (6937): 356-361. 10.1038\/nature01661.","journal-title":"Nature"},{"issue":"Suppl 1","key":"753_CR2","doi-asserted-by":"crossref","first-page":"i103","DOI":"10.1136\/ard.59.suppl_1.i103","volume":"59","author":"MH Schiff","year":"2000","unstructured":"Schiff MH: Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis. 2000, 59 (Suppl 1): i103-i108.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"753_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.berh.2010.02.002","volume":"24","author":"M Niedermeier","year":"2010","unstructured":"Niedermeier M, Pap T, Korb A: Therapeutic opportunities in fibroblasts in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2010, 24 (4): 527-540. 10.1016\/j.berh.2010.02.002.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"753_CR4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbrc.2008.11.002","volume":"378","author":"YR Lee","year":"2010","unstructured":"Lee YR, Kweon SH, Kwon KB, Park JW, Yoon TR, Park BH: Inhibition of IL-1beta-mediated inflammatory responses by the IkappaB alpha super-repressor in human fibroblast-like synoviocytes. Biochem Biophys Res Commun. 2010, 378 (1): 90-94.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"753_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.addr.2006.01.005","volume":"58","author":"S Abramson","year":"2006","unstructured":"Abramson S: Drug delivery in degenerative joint disease: where we are and where to go?. Adv Drug Deliv Rev. 2006, 58 (2): 125-127. 10.1016\/j.addr.2006.01.005.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"753_CR6","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1002\/art.10578","volume":"46","author":"G Nuki","year":"2002","unstructured":"Nuki G, Bresnihan B, Bear MB, McCabe D: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46 (11): 2838-2846. 10.1002\/art.10578.","journal-title":"Arthritis Rheum"},{"issue":"1\u20132","key":"753_CR7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.molimm.2011.08.020","volume":"49","author":"X Niu","year":"2011","unstructured":"Niu X, He D, Deng S, Li W, Xi Y, Xie C, Jiang T, Zhang JZ, Dong C, Chen G: Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis. Mol Immunol. 2011, 49 (1\u20132): 290-296.","journal-title":"Mol Immunol"},{"key":"753_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1749-6632.2009.05159.x","volume":"1182","author":"R Goldbach-Mansky","year":"2009","unstructured":"Goldbach-Mansky R: Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci. 2009, 1182: 111-123. 10.1111\/j.1749-6632.2009.05159.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"25","key":"753_CR9","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1056\/NEJMra040226","volume":"350","author":"JR O'Dell","year":"2004","unstructured":"O'Dell JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004, 350 (25): 2591-2602. 10.1056\/NEJMra040226.","journal-title":"N Engl J Med"},{"issue":"7","key":"753_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard.2008.093690","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, van der Heijde D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009, 68 (7): 1100-1104. 10.1136\/ard.2008.093690.","journal-title":"Ann Rheum Dis"},{"key":"753_CR11","first-page":"485","volume":"3","author":"K Thaler","year":"2009","unstructured":"Thaler K, Chandiramani DV, Hansen RA, Gartlehner G: Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics. 2009, 3: 485-498.","journal-title":"Biologics"},{"issue":"1","key":"753_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/rheumatology\/40.1.62","volume":"40","author":"G Cunnane","year":"2001","unstructured":"Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B: The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford). 2001, 40 (1): 62-69. 10.1093\/rheumatology\/40.1.62.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"753_CR13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L: Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009, 68 (1): 25-32.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"753_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","volume":"32","author":"C Kaiser","year":"2012","unstructured":"Kaiser C, Knight A, Nordstrom D, Pettersson T, Fransson J, Florin-Robertsson E, Pilstrom B: Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012, 32 (2): 295-299. 10.1007\/s00296-011-2096-3.","journal-title":"Rheumatol Int"},{"issue":"3","key":"753_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20021829","volume":"197","author":"C Chaudhury","year":"2003","unstructured":"Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL: The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003, 197 (3): 315-322. 10.1084\/jem.20021829.","journal-title":"J Exp Med"},{"issue":"15","key":"753_CR16","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1021\/bi052628y","volume":"45","author":"C Chaudhury","year":"2006","unstructured":"Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL: Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry. 2006, 45 (15): 4983-4990. 10.1021\/bi052628y.","journal-title":"Biochemistry"},{"issue":"6","key":"753_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1248\/bpb.25.695","volume":"25","author":"U Kragh-Hansen","year":"2002","unstructured":"Kragh-Hansen U, Chuang VT, Otagiri M: Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull. 2002, 25 (6): 695-704. 10.1248\/bpb.25.695.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"753_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","volume":"157","author":"B Elsadek","year":"2011","unstructured":"Elsadek B, Kratz F: Impact of albumin on drug delivery - New applications on the horizon. J Control Release. 2011, 157 (1): 4-28.","journal-title":"J Control Release"},{"issue":"3","key":"753_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Kratz F: Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008, 132 (3): 171-183. 10.1016\/j.jconrel.2008.05.010.","journal-title":"J Control Release"},{"issue":"2","key":"753_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jconrel.2011.11.028","volume":"161","author":"F Kratz","year":"2012","unstructured":"Kratz F, Elsadek B: Clinical impact of serum proteins on drug delivery. J Control Release. 2012, 161 (2): 429-445. 10.1016\/j.jconrel.2011.11.028.","journal-title":"J Control Release"},{"issue":"4","key":"753_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.bbrc.2010.04.134","volume":"396","author":"N Muller","year":"2010","unstructured":"Muller N, Schneider B, Pfizenmaier K, Wajant H: Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun. 2010, 396 (4): 793-799. 10.1016\/j.bbrc.2010.04.134.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"753_CR22","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/art.1780241215","volume":"24","author":"JR Levick","year":"1981","unstructured":"Levick JR: Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 1981, 24 (12): 1550-1560. 10.1002\/art.1780241215.","journal-title":"Arthritis Rheum"},{"key":"753_CR23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-63-1-109","volume":"63","author":"P Wilkinson","year":"1965","unstructured":"Wilkinson P, Jeremy R, Brooks FP, Hollander JL: The Mechanism of Hypoalbuminemia In Rheumatoid Arthritis. Ann Intern Med. 1965, 63: 109-114.","journal-title":"Ann Intern Med"},{"issue":"6","key":"753_CR24","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-99-6-880_2","volume":"99","author":"F Ballantyne","year":"1983","unstructured":"Ballantyne F: Myocardial ischemia and ambulatory monitoring. Ann Intern Med. 1983, 99 (6): 880-881.","journal-title":"Ann Intern Med"},{"issue":"1","key":"753_CR25","first-page":"11","volume":"31","author":"Y Niwa","year":"1990","unstructured":"Niwa Y, Iio A, Niwa G, Sakane T, Tsunematsu T, Kanoh T: Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer. J Clin Lab Immunol. 1990, 31 (1): 11-16.","journal-title":"J Clin Lab Immunol"},{"issue":"9","key":"753_CR26","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.4049\/jimmunol.170.9.4793","volume":"170","author":"A Wunder","year":"2003","unstructured":"Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C: Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 2003, 170 (9): 4793-4801.","journal-title":"J Immunol"},{"issue":"5","key":"753_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/protein\/gzm067","volume":"21","author":"LJ Holt","year":"2008","unstructured":"Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM: Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008, 21 (5): 283-288. 10.1093\/protein\/gzm067.","journal-title":"Protein Eng Des Sel"},{"issue":"6","key":"753_CR28","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/art.21827","volume":"54","author":"K Coppieters","year":"2006","unstructured":"Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, et al: Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006, 54 (6): 1856-1866. 10.1002\/art.21827.","journal-title":"Arthritis Rheum"},{"issue":"17","key":"753_CR29","doi-asserted-by":"publisher","first-page":"12650","DOI":"10.1074\/jbc.M700820200","volume":"282","author":"D Muller","year":"2007","unstructured":"Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann RE: Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007, 282 (17): 12650-12660. 10.1074\/jbc.M700820200.","journal-title":"J Biol Chem"},{"issue":"2","key":"753_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/jpet.102.037002","volume":"303","author":"BL Osborn","year":"2002","unstructured":"Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C: Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002, 303 (2): 540-548. 10.1124\/jpet.102.037002.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"753_CR31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(02)02644-4","volume":"456","author":"BL Osborn","year":"2002","unstructured":"Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ: Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002, 456 (1\u20133): 149-158.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"753_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pep.2010.05.009","volume":"73","author":"L Evans","year":"2010","unstructured":"Evans L, Hughes M, Waters J, Cameron J, Dodsworth N, Tooth D, Greenfield A, Sleep D: The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2010, 73 (2): 113-124. 10.1016\/j.pep.2010.05.009.","journal-title":"Protein Expr Purif"},{"issue":"1","key":"753_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2010.05.020","volume":"147","author":"S Ikuta","year":"2010","unstructured":"Ikuta S, Chuang VT, Ishima Y, Nakajou K, Furukawa M, Watanabe H, Maruyama T, Otagiri M: Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications. J Control Release. 2010, 147 (1): 17-23. 10.1016\/j.jconrel.2010.05.020.","journal-title":"J Control Release"},{"issue":"6","key":"753_CR34","first-page":"781","volume":"24","author":"MM Griffiths","year":"1981","unstructured":"Griffiths MM, Eichwald EJ, Martin JH, Smith CB, DeWitt CW: Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum. 1981, 24 (6): 781-789.","journal-title":"I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum"},{"issue":"5748","key":"753_CR35","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/283666a0","volume":"283","author":"JS Courtenay","year":"1980","unstructured":"Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B: Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980, 283 (5748): 666-668. 10.1038\/283666a0.","journal-title":"Nature"},{"issue":"5","key":"753_CR36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.0818-9641.2003.01185.x","volume":"81","author":"IK Campbell","year":"2003","unstructured":"Campbell IK, Roberts LJ, Wicks IP: Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol. 2003, 81 (5): 354-366. 10.1046\/j.0818-9641.2003.01185.x.","journal-title":"Immunol Cell Biol"},{"issue":"4\u20135","key":"753_CR37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6101(02)00027-8","volume":"13","author":"K Ishihara","year":"2002","unstructured":"Ishihara K, Hirano T: IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002, 13 (4\u20135): 357-368.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"753_CR38","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.4049\/jimmunol.145.12.4181","volume":"145","author":"P Seckinger","year":"1990","unstructured":"Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG: Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol. 1990, 145 (12): 4181-4184.","journal-title":"J Immunol"},{"issue":"5","key":"753_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/art.1780390513","volume":"39","author":"LA Joosten","year":"1996","unstructured":"Joosten LA, Helsen MM, van de Loo FA, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha\/beta, and IL-1Ra. Arthritis Rheum. 1996, 39 (5): 797-809. 10.1002\/art.1780390513.","journal-title":"Arthritis Rheum"},{"issue":"2 Suppl","key":"753_CR40","first-page":"S110","volume":"58","author":"LA Joosten","year":"2008","unstructured":"Joosten LA, Helsen MM, van de Loo FA, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha\/beta and IL-1Ra. Arthritis Rheum. 2008, 58 (2 Suppl): S110-122.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"753_CR41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2249.1994.tb06517.x","volume":"95","author":"WB van den Berg","year":"1994","unstructured":"van den Berg WB, Joosten LA, Helsen M, van de Loo FA: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol. 1994, 95 (2): 237-243.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"753_CR42","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.4049\/jimmunol.165.12.7240","volume":"165","author":"RO Williams","year":"2000","unstructured":"Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN: Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha\/anti-CD4 therapy. J Immunol. 2000, 165 (12): 7240-7245.","journal-title":"J Immunol"},{"issue":"3","key":"753_CR43","doi-asserted-by":"publisher","first-page":"R122","DOI":"10.1186\/ar748","volume":"5","author":"GM Campo","year":"2003","unstructured":"Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A: Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther. 2003, 5 (3): R122-131. 10.1186\/ar748.","journal-title":"Arthritis Res Ther"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6750-12-68.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6750-12-68\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6750-12-68.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T22:59:28Z","timestamp":1687733968000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/1472-6750-12-68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1186\/1472-6750-12-68","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]},"article-number":"68"}}